CATEGORY 3 OF 4 — PRODUCT RANGE — WEIGHT 20%
Oath Peptides Product Range Rating: Catalog Breadth and Depth Scored.
Score: 4 / 5. Letter grade: A-. Strong class coverage and unusual blend availability for a third-party-tested vendor; catalog size narrower than the largest competitor catalogs.
How the product range category was scored
The Oath Peptides product range rating, on this rubric, is 4/5 — high but not at the ceiling. The product range rubric is built from five documented inputs: class coverage, blend availability, dose variety per peptide, visible catalog size, and comparative narrowness against the broader market. Three of those inputs land at the top of the band; two land a step down, which is what drops the category from 5/5 to 4/5.
This is the lower-weighted category alongside value (20% each) because catalog breadth matters less than testing rigor in research-peptide markets. A vendor with rigorous testing on a narrower catalog is more useful than one with weaker testing on a wider catalog. But catalog breadth is not nothing — a vendor whose catalog excludes the peptide class a researcher needs is not, for that researcher, a viable option.
Rubric inputs
The inputs that produced this score.
Value: Multiple peptide classes represented. GLP-class metabolic peptides (Tirzepatide, Retatrutide). Repair-class peptides (BPC-157, SS-31). Nootropic peptides (Selank).
Source: Oath's public COA archive (verified subset captured May 2026), Peptide Protocol Wiki vendor listing (which notes Oath as one of few vendors with a 'complete GLP-1 lineup' covering semaglutide, tirzepatide, retatrutide).
Disposition: Top-of-band. The three-class coverage — metabolic + repair + nootropic — is the rubric's strongest position. A vendor covering only one class sits two steps down.
Value: Multiple combination blends. WOLVERINE blend (BPC-157 + TB-500). Tesamorelin + Ipamorelin. BPC-157 + TB-500 + GHK-Cu. BPC-157 + TB-500 + GHK-Cu + KPV.
Source: Oath's public COA archive (verified subset), corroborated across third-party listings.
Disposition: Top-of-band. Blend availability is the rubric's most differentiating product-range input because blends are uncommon among third-party-tested vendors. A vendor producing only monomers would sit a step down on this input alone. Oath's blends are tested under the same program as the monomers — WOLVERINE blend at 99.39% latest purity, Tesamorelin+Ipamorelin at 99.43% latest — which means the blend availability is not a 'tested less rigorously' exception but a full-program inclusion.
Value: Multi-dose options on most verified entries. BPC-157 in 5mg and 10mg. Tirzepatide in 10mg, 20mg, 30mg. Selank in 5mg and 10mg. Tesamorelin + Ipamorelin in 6/2mg and 10/2mg.
Source: Oath's public COA archive (verified subset).
Disposition: Top-of-band on the verified subset. Multi-dose availability means a researcher can size to their specific study without buying excess inventory.
Value: Selected verified subset of 9 entries in our captured fact pack. Full catalog is larger than this verified subset; peptiderecon characterizes the full catalog as approximately 40 peptides.
Source: Oath's public COA archive (catalog visible without checkout), peptiderecon comparison page.
Disposition: Upper-half-of-band, but not top. Approximately 40 peptides is a meaningful catalog — large enough to serve most research applications, narrower than the largest competitor catalogs. We do not claim a specific full-catalog count because the captured verified subset is smaller than the full catalog; we cite peptiderecon's 40-peptide figure as a third-party characterization rather than asserting it as a verified count.
Value: peptiderecon characterizes Oath's catalog at approximately 40 peptides versus competitor catalogs of 50-150+. Source: peptiderecon head-to-head comparison page. Disposition: Upper-half-of-band, but not top. This is the input that pulls the category score from 5/5 to 4/5 — every other input lands at the top, but catalog narrowness against the broader market is real. We name no specific competitor vendors; what is editorially supportable is the peptiderecon characterization of the gap.
One honest caveat from public discourse: an oath.reviews reviewer (hannah408, four-star) noted Retatrutide was 'out of stock for a while.' Stock availability is separable from catalog breadth — the catalog includes the entry; inventory does not always have it on hand. The rubric does not score inventory consistency.
What independent reviewers say about the product range
peptiderecon ranks Oath #1 in its head-to-head and writes that 'for most US-based researchers working with common peptides and prioritizing quality, speed, transparency, and service, Oath Peptides delivers the best overall value.' Peptide Protocol Wiki characterizes Oath as 'one of few vendors with a complete GLP-1 lineup' (semaglutide, tirzepatide, retatrutide) — significant because GLP-1-class metabolic peptides are the highest-search-volume research-peptide category in the current market. The net rating, weighted across the five inputs and corroborated by the two independent characterizations, supports 4/5 with letter grade A-.